The Interuniversity Cardiology Institute of the Netherlands   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Netherlands

Organization Overview

First Clinical Trial
2007
NCT00449488
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

eplerenone (inspra) (1 trial)

Drugs in Phase 2 Trials (2)

epoetin (Epogen) (1 trial)

losartan (cozaar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 3)

Congenital Abnormalities (Phase 2)

Heart Defects, Congenital (Phase 2)

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

Tetralogy of Fallot (Phase 2)

Ventricular Dysfunction (Phase 2)

Ventricular Dysfunction, Right (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3